WASHINGTON (Reuters)—The U.S. Food and Drug Administration on Friday approved a cheaper, biosimilar version of AbbVie’s top-selling arthritis drug, adalimumab (Humira).
The drug, adalimumab-atto (Amjevita), is made by biotechnology company Amgen Inc. and was approved to treat rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, psoriasis and other conditions.
Amjevita is the fourth biosimilar to be approved by the FDA. Last month, it approved Novartis AG’s biosimilar version of Amgen’s arthritis drug, etanercept (Enbrel).